

Fragment-based drug discovery using cryo-EM – a future perspective

Michael Saur, *Astex Pharmaceuticals, Cambridge, UK*

Abstract

Advances made in the past decade in cryogenic electron microscopy (cryo-EM) structure determination have significantly increased interest in the technology from the pharmaceutical industry. Astex has heavily invested into cryo-EM and developed a streamlined pipeline to facilitate fragment-based drug discovery (FBDD) using cryo-EM. This presentation will give an overview of the cryo-EM journey which Astex has embarked upon since 2016 and focus on the developments we deem necessary to make the technology an even more important tool for future drug discovery programmes.